Retatrutide
The first weight loss drug to target three appetite and metabolism hormones at once (GIP, GLP-1, and glucagon). In early trials, people lost up to 24% of their body weight — the highest ever recorded for any weight loss medication. The third hormone target (glucagon) helps burn more calories and reduce liver fat, going beyond what current drugs like semaglutide or tirzepatide can achieve. Still in clinical trials.
Dosage
12 mg subcutaneous once weekly (optimal Phase 2 dose)
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (weekly)
Get Research-Grade Retatrutide
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
Up to 24% body weight reduction in Phase 2 trials — highest recorded for any anti-obesity medication.
Energy Expenditure
Glucagon receptor activation drives thermogenesis and increases metabolic rate.
Liver Fat Reduction
Glucagon-driven hepatic fat oxidation directly reduces liver fat content.
Blood Sugar Control
Triple receptor action provides comprehensive glycemic improvement.
Mechanism of Action
Retatrutide is a triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors — the first molecule to target all three pathways. Each receptor system contributes distinct metabolic effects that combine to produce unprecedented weight loss results in clinical trials.
The GLP-1 component suppresses appetite through hypothalamic signaling and slows gastric emptying, while the GIP component enhances beta-cell insulin secretion and may improve lipid handling in adipose tissue. What sets retatrutide apart is the addition of glucagon receptor agonism. Glucagon receptors in the liver stimulate glycogenolysis, gluconeogenesis, and critically, hepatic fatty acid oxidation. In brown and beige adipose tissue, glucagon signaling drives thermogenesis — literally increasing the body's energy expenditure by converting calories to heat rather than storing them as fat.
The glucagon component also has significant implications for liver health, as it directly promotes the breakdown of hepatic triglycerides, making retatrutide particularly promising for metabolic-associated steatotic liver disease (MASLD/NASH). The molecular design balances the three receptor affinities carefully — too much glucagon agonism could raise blood glucose, but the concurrent GLP-1 and GIP activation provides sufficient insulinotropic counterbalance to maintain glycemic control. Phase 2 trials demonstrated up to 24% body weight reduction at the highest dose, representing the largest weight loss achieved by any anti-obesity medication to date.
Regulatory Status
Not yet FDA approved. Phase 3 clinical trials ongoing (Eli Lilly). Expected approval timeline mid-2026.
Risks & Safety
Common
nausea (25-45%), diarrhea, vomiting, constipation, reduced appetite.
Serious
slightly elevated heart rate, inflammation of the pancreas, gallstones.
Rare
thyroid tumour concern (seen with similar drugs in animals), severe allergic reactions.
Compare Retatrutide With
Research Papers
30Published: January 25, 2026
AI Summary
Abstract too short to summarize.
Published: March 4, 2026
AI Summary
Dual and triple incretin agonists like tirzepatide and retatrutide improve blood sugar, weight, and liver outcomes. The review summarizes their mechanisms, clinical progress, and limitations.
Published: January 22, 2026
AI Summary
Retatrutide, a triple GLP-1/GIP/glucagon agonist, achieves weight loss comparable to bariatric surgery in trials. It may be a major advance in obesity pharmacotherapy.
Published: January 29, 2026
AI Summary
The review explains how glucagon receptor agonism boosts energy expenditure and how combining it with other incretins leads to dual and triple agonists like retatrutide.
Published: November 12, 2025
AI Summary
The review covers FDA-approved and emerging obesity drugs. Retatrutide and other multi-agonist agents show greater efficacy than earlier options.
Published: November 22, 2025
AI Summary
The review summarizes trials of diabetes and kidney drugs. Retatrutide and other GLP-1-based agents may help slow kidney disease progression.
Published: November 23, 2025
AI Summary
The review outlines GLP-1 receptor agonists for obesity and their benefits beyond weight loss, including cardiovascular and metabolic effects.
Published: November 25, 2025
AI Summary
Multi-agonist drugs like tirzepatide, CagriSema, and retatrutide achieve strong weight loss and metabolic improvements. The review covers their mechanisms and clinical data.
Published: December 23, 2025
AI Summary
Abstract too short to summarize.
Published: October 28, 2025
AI Summary
Abstract too short to summarize.
Published: September 23, 2025
AI Summary
GLP-1, dual, and triple agonists improved weight and insulin sensitivity in PCOS more than metformin or birth control. Retatrutide showed the strongest effects.
Published: January 14, 2026
AI Summary
Abstract too short to summarize.
Published: November 30, 2025
AI Summary
Retatrutide improved steatohepatitis in a 31-day mouse model. The model may be useful for testing drug interventions.
Published: October 6, 2025
AI Summary
The review covers novel GLP-1-based drugs including retatrutide. Triple agonists show the strongest metabolic effects.
Published: December 29, 2025
AI Summary
Glucagon-based multi-agonists like retatrutide drive weight loss and liver benefits. The review explains mechanisms and ongoing trials.
Published: October 6, 2025
AI Summary
Anti-obesity drugs, including retatrutide, show promise in fatty liver disease. The review summarizes efficacy and safety in MASLD/MASH.
Published: September 8, 2025
AI Summary
Abstract too short to summarize.
Published: September 14, 2025
AI Summary
GLP-1-based drugs cause muscle loss along with fat loss. The review suggests strategies to preserve muscle during weight loss.
Published: October 8, 2025
AI Summary
A triple agonist with weaker GIP activity matched retatrutide's metabolic effects. The work suggests receptor activation ratios can be optimized.
Published: August 25, 2025
AI Summary
Retatrutide and other incretin co-agonists produce strong weight and metabolic benefits. The review summarizes their cardiometabolic effects.
Published: December 7, 2025
AI Summary
Abstract too short to summarize.
Published: September 2, 2025
AI Summary
Abstract too short to summarize.
Published: November 25, 2025
AI Summary
Retatrutide and other multi-agonist drugs can achieve 15–25% weight loss. The review covers efficacy, safety, and challenges in obesity treatment.
Published: July 27, 2025
AI Summary
GLP-1-based therapies have transformed obesity care. Retatrutide and oral agents may further improve outcomes, but cost and access remain barriers.
Published: July 27, 2025
AI Summary
The review outlines the rationale for triple agonists and summarizes clinical data on retatrutide.
Published: July 23, 2025
AI Summary
Glucagon-based multi-agonists like retatrutide drive significant weight loss. The review discusses their role in obesity management.
Published: September 28, 2025
AI Summary
Retatrutide and other incretin-based agents are advancing obesity pharmacotherapy. The review covers future treatment options.
Published: June 30, 2025
AI Summary
Abstract too short to summarize.
Published: October 28, 2025
AI Summary
Retatrutide lowered triglycerides and LDL cholesterol partly by reducing ANGPTL3/8. The finding may explain some of its lipid benefits.
Published: July 22, 2025
AI Summary
Semaglutide, tirzepatide, and retatrutide reduced the subjective effects of alcohol in rats. The work supports their potential use in alcohol use disorder.
Frequently Asked Questions
What is Retatrutide?
The first weight loss drug to target three appetite and metabolism hormones at once (GIP, GLP-1, and glucagon). In early trials, people lost up to 24% of their body weight — the highest ever recorded for any weight loss medication. The third hormone target (glucagon) helps burn more calories and reduce liver fat, going beyond what current drugs like semaglutide or tirzepatide can achieve. Still in clinical trials.
What is Retatrutide used for?
The first weight loss drug to target three appetite and metabolism hormones at once (GIP, GLP-1, and glucagon). In early trials, people lost up to 24% of their body weight — the highest ever recorded for any weight loss medication. The third hormone target (glucagon) helps burn more calories and reduce liver fat, going beyond what current drugs like semaglutide or tirzepatide can achieve. Still in clinical trials.
What is the dosage for Retatrutide?
Clinical trials: 1-12 mg subcutaneous once weekly, with dose escalation over initial weeks. Optimal dose: 12 mg subcutaneous once weekly based on Phase 2 data. Phase 3 dosing protocols pending.
What are the side effects of Retatrutide?
Common: nausea (25-45%), diarrhea, vomiting, constipation, reduced appetite. Serious: slightly elevated heart rate, inflammation of the pancreas, gallstones. Rare: thyroid tumour concern (seen with similar drugs in animals), severe allergic reactions.
How does Retatrutide work?
Retatrutide is a triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors — the first molecule to target all three pathways. Each receptor system contributes distinct metabolic effects that combine to produce unprecedented weight loss results in clinical trials. The GLP-1 component suppresses appetite through hypothalamic signaling and slows gastric emptying, while the GIP component enhances beta-cell insulin secretion and may improve lipid handling in adipose tissue. What sets retatrutide apart is the addition of glucagon receptor agonism. Glucagon receptors in the liver stimulate glycogenolysis, gluconeogenesis, and critically, hepatic fatty acid oxidation. In brown and beige adipose tissue, glucagon signaling drives thermogenesis — literally increasing the body's energy expenditure by converting calories to heat rather than storing them as fat. The glucagon component also has significant implications for liver health, as it directly promotes the breakdown of hepatic triglycerides, making retatrutide particularly promising for metabolic-associated steatotic liver disease (MASLD/NASH). The molecular design balances the three receptor affinities carefully — too much glucagon agonism could raise blood glucose, but the concurrent GLP-1 and GIP activation provides sufficient insulinotropic counterbalance to maintain glycemic control. Phase 2 trials demonstrated up to 24% body weight reduction at the highest dose, representing the largest weight loss achieved by any anti-obesity medication to date.
How is Retatrutide administered?
Retatrutide is administered via subcutaneous injection (weekly).
What is the half-life of Retatrutide?
The half-life of Retatrutide is 144 hours (6 days).
Is Retatrutide legal?
Not yet FDA approved. Phase 3 clinical trials ongoing (Eli Lilly). Expected approval timeline mid-2026.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.